Cleveland, OH Clinical Trials Report — May 2026

For Cleveland residents considering participation in clinical research, May 2026 offers important opportunities, particularly for those looking to act quickly. A total of 87 clinical trials are slated to conclude enrollment within the next 90 days, making prompt action essential for interested individuals.

Among these rapidly closing studies, 7 trials are still actively seeking healthy volunteers. These opportunities allow individuals without specific health conditions to contribute to medical advancements before their enrollment windows close.

New Research Horizons in Cleveland

This month, Cleveland saw the opening of 18 new clinical trials, a notable increase compared to the 12 new trials launched in April 2026 and the 12 in March 2026. This brings the total number of actively recruiting clinical trials in Cleveland, OH, to 1,223 across 341 research facilities, highlighting the city's dynamic research environment.

May brings several high-profile new trials to Cleveland, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• AstraZeneca is sponsoring NCT07611110, "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)," a Phase 3 study involving 670 participants. The study intends to demonstrate the superiority of AZD2265 relative to standard of care treatments by assessing radiographic progression-free survival and overall survival in participants with metastatic castration-resistant prostate cancer.
• Another significant study from AstraZeneca is NCT07608354, a Phase 2 trial for 326 participants titled "A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM." This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 in adult participants with Transthyretin-mediated amyloid cardiomyopathy.
• The Canopy Cancer Collective, LLC is leading NCT07605702, "The Canopy Cancer Collective Clinical Registry Protocol," a large observational registry protocol aiming for 100,000 participants to systematically collect comprehensive data on gastrointestinal cancer patients.
• Ohio State University is sponsoring NCT07567040, "Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial," a Phase 3 study with 664 participants. This trial will test whether the onset of nearsightedness is delayed in children randomized to nightly 0.05% atropine drops compared to placebo.

New trials this month are exploring a range of conditions, with the most frequent being major depressive disorder (2 trials), metastatic castration-resistant prostate cancer (2 trials), and obesity (2 trials). Drug trials account for the largest share of new studies, with 9 new drug trials, followed by 4 other types of studies, 3 behavioral studies, and 3 device studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 18 new trials launched this month, 4 are actively seeking healthy volunteers. Across Cleveland, a total of 91 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Cleveland's Leading Research Facilities

Cleveland is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Cleveland Clinic (341 trials)
• Cleveland Clinic Foundation (148 trials)
• University Hospitals Cleveland Medical Center (134 trials)
• Case Western Reserve University (81 trials)
• MetroHealth Medical Center (38 trials)
• Research Site (33 trials)
• The Cleveland Clinic Foundation (27 trials)
• Rainbow Babies and Childrens Hospital (25 trials)
• Louis Stokes VA Medical Center, Cleveland, OH (20 trials)
• Cleveland Clinic Main Campus (17 trials)
• Cleveland Clinic Cancer Center/Fairview Hospital (17 trials)
• University Hospitals (13 trials)

These institutions offer a broad spectrum of research, from comprehensive medical studies at the Cleveland Clinic and University Hospitals Cleveland Medical Center, to specialized research at Case Western Reserve University and Rainbow Babies and Childrens Hospital.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various neurological conditions, cancers, and acute injuries are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Parkinson's disease (2 trials)
• Prostate cancer (2 trials)
• Glioblastoma (2 trials)
• Metastatic cancer (2 trials)
• Rotator cuff tears (2 trials)
• Stroke (2 trials)
• Acute kidney injury (2 trials)
• Breast cancer (2 trials)
• Glioblastoma multiforme (2 trials)
• Advanced solid tumor (2 trials)

Broadening Your Search: Nearby Options

While Cleveland offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Ohio. Cities with active trials include Columbus (25 trials), Cincinnati (9 trials), Maumee (3 trials), Dayton (3 trials), South Euclid (1 trial), Vandalia (1 trial), Beachwood (1 trial), and Westlake (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 18 new trials launched this month, 14 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 5 new trials include children, 2 are female-only, and 2 are male-only. Academic institutions and other organizations continue to play a vital role in Cleveland's research ecosystem, with The Cleveland Clinic (3 trials), Case Western Reserve University (1 trial), and MetroHealth Medical Center (1 trial) sponsoring new studies. Industry sponsors like AstraZeneca (2 trials), Definium Therapeutics US, Inc. (1 trial), Eli Lilly and Company (1 trial), and Canopy Cancer Collective, LLC (1 trial) are also driving significant research efforts.

As we move through May, Cleveland's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.